Last Updated: November 10, 2026

Details for New Drug Application (NDA): 205858

NDA 205858 describes ZYDELIG, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the ZYDELIG profile page.

The generic ingredient in ZYDELIG is idelalisib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the idelalisib profile page.

Summary for 205858

Tradename:	ZYDELIG
Applicant:	Gilead Sciences Inc
Ingredient:	idelalisib
Patents:	4

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 205858

Generic Entry Date for 205858^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: 9,469,643 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205858

Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Suppliers and Packaging for NDA: 205858

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ZYDELIG	idelalisib	TABLET;ORAL	205858	NDA	Gilead Sciences, Inc.	61958-1701	61958-1701-1	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1701-1)
ZYDELIG	idelalisib	TABLET;ORAL	205858	NDA	Gilead Sciences, Inc.	61958-1702	61958-1702-1	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1702-1)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	100MG
Approval Date:	Jul 23, 2014	TE:		RLD:	Yes
Patent:	10,730,879	Patent Expiration:	Mar 5, 2033	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	8,865,730	Patent Expiration:	Mar 5, 2033	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
Patent:	9,469,643	Patent Expiration:	Sep 2, 2033	Product Flag?		Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 205858

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014	9,149,477	⤷ Start Trial
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014	6,949,535	⤷ Start Trial
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014	6,800,620	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.